Basilea Pharmaceutica Ltd. Logo
 

Anti-Infectives 2014

 
 
 

Ceftobiprole

  • Abbanat D, Shang W, Amsler K, Santoro C, Baum E, Crespo-Carbone S, Lynch AS. Evaluation of the in vitro activities of ceftobiprole and comparators in staphylococcal colony or microtitre plate biofilm assays. Int J Antimicrob Agents. 2014; 43(1): 32-39.
  • Awad SS, Rodriguez AH, Chuang Y-C, Marjanek Z, Pareigis AJ, Reis G, Scheeren TWL, Sánchez AS, Zhou X, Saulay M, Engelhardt M. A phase 3 randomized double-blind comparison of ceftobiprole medocaril versus ceftazidime plus linezolid for the treatment of hospital-acquired pneumonia. Clin Infect Dis. 2014; 59(1): 51-61.
  • Barbour AM, Schmidt S, Zhuang L, Rand K, Derendorf H. Application of pharmacokinetic/pharmacodynamic modelling and simulation for the prediction of target attainment of ceftobiprole against meticillin-resistant Staphylococcus aureus using minimum inhibitory concentration and time-kill curve based approaches. Int J Antimicrob Agents. 2014; 43(1): 60-67.
  • Barnea Y, Navon-Venezia S, Kuzmenko B, Artzi N, Carmeli Y. Ceftobiprole medocaril is an effective treatment against methicillin-resistant Staphylococcus aureus (MRSA) mediastinitis in a rat model. Eur J Clin Microbiol Infect Dis. 2014; 33(3): 325-329.
  • Chen Y-H, Liu C-Y, Ko W-C, Liao C-H, Lu P-L, Huang C-H, Lu C-T, Chuang Y-C, Tsao S-M, Chen Y-S, Liu Y-C, Chen W-Y, Jang T-N, Lin H-C, Chen C-M, Shi Z-Y, Pan S-C, Yang J-L, Kung H-C, Liu C-E, Cheng Y-J, Liu J-W, Sun W, Wang L-S, Yu K-W, Chiang P-C, Lee M-H, Lee C-M, Hsu G-J, Hsueh P-R. Trends in the susceptibility of methicillin-resistant Staphylococcus aureus to nine antimicrobial agents, including ceftobiprole, nemonoxacin, and tyrothricin: Results from the Tigecycline in Vitro Surveillance in Taiwan (TIST) study, 2006-2010. Eur J Clin Microbiol Infect Dis. 2014; 33(2): 233-239.
  • Curcio D. Multidrug-resistant Gram-negative bacterial infections: Are you ready for the challenge? Curr Clin Pharmacol. 2014; 9(1): 27-38.
  • Farrell DJ, Flamm RK, Sader HS, Jones RN. Activity of ceftobiprole against methicillin-resistant Staphylococcus aureus strains with reduced susceptibility to daptomycin, linezolid or vancomycin, and strains with defined SCCmec types. Int J Antimicrob Agents. 2014; 43(4): 323-327.
  • Farrell DJ, Flamm RK, Sader HS, Jones RN. Ceftobiprole activity against over 60,000 clinical bacterial pathogens isolated in Europe, Turkey, and Israel from 2005 to 2010. Antimicrob Agents Chemother. 2014; 58(7): 3882-3888.
  • Kumar KM, Anitha P, Sivasakthi V, Bag S, Lavanya P, Anbarasu A, Ramaiah S. In silico study on Penicillin derivatives and Cephalosporins for upper respiratory tract bacterial pathogens. 3 Biotech. 2014; 4(3): 241-251.
  • Muller AE, Punt N, Mouton JW. Exposure to ceftobiprole is associated with microbiological eradication and clinical cure in patients with nosocomial pneumonia. Antimicrob Agents Chemother. 2014; 58(5): 2512-2519.
  • Salem AH, Zhanel GG, Ibrahim SA, Noreddin AM. Monte Carlo simulation analysis of ceftobiprole, dalbavancin, daptomycin, tigecycline, linezolid and vancomycin pharmacodynamics against intensive care unit-isolated methicillin-resistant Staphylococcus aureus. Clin Exp Pharmacol Physiol. 2014; 41(6): 437-443.

  • ECCMID, 2014, O151 / Early clinical improvement and clinical cure in a randomised controlled phase 3 study of ceftobiprole versus ceftazidime/linezolid in patients with hospital-acquired pneumonia. Scheeren T,  Rodriguez A, Zhou X, Saulay M, Engelhardt M.
  • ECCMID, 2014, eP431 / Early clinical response in a randomised controlled phase 3 study of ceftobiprole versus ceftriaxone with or without linezolid in patients with community-acquired pneumonia requiring hospitalisation. Welte T, Herrera G, Chuang Y-C, Demange A, Engelhardt M.
  • ECCMID, 2014, eP187 / Antimicrobial activity of ceftobiprole tested against staphylococci and streptococci from European countries and Israel (2013). Flamm R K, Farrell D J, Streit J M, Sader H S, Jones R N.
  • ECCMID, 2014, eP188 / Ceftobiprole activity tested against bacterial isolates from hospitalized patients with pneumonia in European hospitals and Israel (2013). Flamm R K, Farrell D J, Streit J M, Sader H S, Jones R N.

 

Isavuconazole

  • Chowdhary A, Kathuria S, Prakash A, Meis JF. Correlation of CLSI and EUCAST in-vitro antifungal susceptibility with clinical outcome of patients with AIDS associated cryptococcosis from India. Mycoses. 2014; 57: 50.
  • Desai A, Yamazaki T, Kowalski D, Lademacher C, Pearlman H, Rammelsberg D, Townsend R. Effect of multiple doses of isavuconazole on the pharmacokinetics of metformin in healthy subjects. Clin Pharmacol Ther. 2014; 95: S41.
  • Ervens J, Ghannoum M, Graf B, Schwartz S. Successful isavuconazole salvage therapy in a patient with invasive mucormycosis. Infection. 2014; 42(2): 429-432.
  • Luo G, Gebremariam T, Lee H, Edwards Jr JE, Kovanda L, Ibrahim AS. Isavuconazole therapy protects immunosuppressed mice from mucormycosis. Antimicrob Agents Chemother. 2014; 58(4): 2450-2453.
  • Najafzadeh MJ, Sutton DA, Keisari MS, Zarrinfar H, De Hoog GS, Chowdhary A, Meis JF. In vitro activities of eight antifungal drugs against 104 environmental and clinical isolates of Aureobasidium pullulans. Antimicrob Agents Chemother. 2014; 58(9): 5629-5631. [In Process]
  • Peixoto D, Gagne LS, Hammond SP, Gilmore ET, Joyce AC, Soiffer RJ, Marty FM. Isavuconazole treatment of a patient with disseminated mucormycosis. J Clin Microbiol. 2014; 52(3): 1016-1019.
  • Pfaller MA, Castanheira M, Messer SA, Rhomberg PR, Jones RN. Comparison of EUCAST and CLSI broth microdilution methods for the susceptibility testing of 10 systemically active antifungal agents when tested against Candida spp. Diagn Microbiol Infect Dis. 2014; 79(2): 198-204.
  • Prakash A, Hagen F, Kathuria S, Meis JF, Chowdhary A. Genotypic diversity within clinical and environmental Cryptococcus neoformans var grubii population in India. Mycoses. 2014; 57: 78.
  • Prakash A, Wankhede S, Singh PK, Agarwal K, Kathuria S, Sengupta S, Barman P, Meis JF, Chowdhary A. First neonatal case of fungaemia due to Pseudozyma aphidis and a global literature review. Mycoses. 2014; 57(1): 64-68.
  • Taj-Aldeen SJ, Abdulwahab A, Kolecka A, Deshmukh A, Meis JF, Boekhout T. Uncommon opportunistic yeast bloodstream infections from Qatar. Med Mycol. 2014; 52(5): 549-553.
  • Taj-Aldeen SJ, Kolecka A, Boesten R, Alolaqi A, Almaslamani M, Chandra P, Meis JF, Boekhout T. Epidemiology of candidemia in Qatar, the Middle East: Performance of MALDI-TOF MS for the identification of Candida species, species distribution, outcome, and susceptibility pattern. Infection. 2014; 42(2): 393-404.
  • Townsend R, Yamazaki T, Kowalski D, Lademacher C, Pearlman H, Rammelsberg D, Desai A. Effect of multiple doses of isavuconazole on the pharmacokinetics of oral contraceptive with ethinyl estradiol and norethindrone in healthy subjects. Clin Pharmacol Ther. 2014; 95: S90-S91.
  • Yamazaki T, Desai A, Kowalski D, Lademacher C, Pearlman H, Rammelsberg D, Townsend R. Effect of multiple doses of isavuconazole on the pharmacokinetics of methotrexate in healthy subjects. Clin Pharmacol Ther. 2014; 95: S93.

  • ECCMID, 2014, O230a / A phase 3 randomised, double-blind trial evaluating isavuconazole vs. voriconazole for the primary treatment of invasive fungal disease caused by Aspergillus spp. or other filamentous fungi (SECURE). Maertens J, Patterson T, Rahav G, Kontoyiannis D, Marr K, Maher R, Lee M, Zeiher B, Ullmann A.
  • ECCMID, 2014, P1698 / Pharmacodynamics of the new azole isavuconazole (ISA) in an Aspergillus fumigatus mouse infection model. Seyedmousavi S, Meis J F, Brüggemann R J M, Melchers W J G, Verweij P E, Mouton J W.
  • ECCMID, 2014, P0106 / In vivo efficacy of isavuconazole and amphotericin B in a non-neutropenic murine model of disseminated Absidia corymbifera. Warn P, Sharp A.

 

BAL30072

  • Landman D, Singh M, El-Imad B, Miller E, Win T, Quale J. In vitro activity of the siderophore monosulfactam BAL30072 against contemporary Gram-negative pathogens from New York City, including multidrug-resistant isolates. Int J Antimicrob Agents. 2014; 43(6): 527-532.

  • ECCMID, 2014, P0296 / Activity of BAL30072 alone and in combination with carbapenems against Gram-negative bacteria. Morrissey I, Siegmund C, Genet E, Neri M, Hawser S, Jones M, Page M, Santerre Henriksen A.
  • ECCMID, 2014, P0297 / Determination of the effect of blaNDM-1 gene copy number on the activity of BAL30072 alone and in combination with meropenem against clinical NDM-1 positive bacteria. Jones L, Page MGP, Jones ME, Walsh TR.
 
Info